Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.533
+0.005 (0.98%)
At close: Feb 21, 2025, 4:00 PM
0.540
+0.007 (1.24%)
After-hours: Feb 21, 2025, 7:13 PM EST
Mersana Therapeutics Employees
Mersana Therapeutics had 123 employees as of December 31, 2023. The number of employees decreased by 105 or -46.05% compared to the previous year.
Employees
123
Change (1Y)
-105
Growth (1Y)
-46.05%
Revenue / Employee
$283,228
Profits / Employee
-$606,659
Market Cap
65.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
MRSN News
- 15 days ago - Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 6 weeks ago - Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? - Benzinga
- 6 weeks ago - Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) - GlobeNewsWire
- 6 weeks ago - Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer - GlobeNewsWire
- 2 months ago - Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable - Seeking Alpha
- 3 months ago - Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewsWire